OMNIPAQUE
Drug
GE HEALTHCARE
Total Payments
$779,991
Transactions
32
Doctors
8
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $198,551 | 12 | 0 |
| 2022 | $179,552 | 4 | 0 |
| 2019 | $10,473 | 4 | 1 |
| 2017 | $391,415 | 12 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $767,576 | 18 | 98.4% |
| Consulting Fee | $6,000 | 2 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,600 | 3 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $500.00 | 1 | 0.1% |
| Food and Beverage | $315.46 | 8 | 0.0% |
Payments by Type
Research
$767,576
18 transactions
General
$12,415
14 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF URATE EVALUATING INOSINE TREATMENT TO SLOW CLINICAL DECLINE IN EARLY PARKINSONS DISEASE | GE HEALTHCARE | $384,600 | 0 |
| Contrast Enhanced Mammography Imaging Screening Trial (CMIST) | GE HEALTHCARE | $198,551 | 0 |
| DEVELOPMENT OF TECHNOLOGY TO EXTEND SCOPE OF MRI IN ORTHOPEDICS | GE HEALTHCARE | $151,351 | 0 |
| LOW-OSMOLAR CONTRAST TAGGING IN MINIMAL CATHARTIC CT COLONOGRAPHY | GE HEALTHCARE | $28,201 | 0 |
| EARLY STAGE CHRONIC KIDNEY DISEASE IN HIV INFECTED INDIVIDUALS (MR BEAN STUDY) | GE HEALTHCARE | $4,873 | 0 |
Top Doctors Receiving Payments for OMNIPAQUE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Topeka, KS | $768,076 | 19 |
| , MD | Diagnostic Radiology | Boston, MA | $11,639 | 6 |
| , MD | Diagnostic Radiology | Madison, WI | $39.43 | 1 |
| , M.D | Diagnostic Radiology | Durham, NC | $39.43 | 1 |
| , M.D | Diagnostic Radiology | San Francisco, CA | $39.43 | 1 |
| , MD | Diagnostic Radiology | Boston, MA | $39.43 | 1 |
| , M.D | Diagnostic Radiology | Baltimore, MD | $39.43 | 1 |
| , MD | Diagnostic Radiology | Dallas, TX | $39.43 | 1 |
| , M.D | Diagnostic Radiology | San Francisco, CA | $39.43 | 1 |
Ad
Manufacturing Companies
- GE HEALTHCARE $779,991
Product Information
- Type Drug
- Total Payments $779,991
- Total Doctors 8
- Transactions 32
About OMNIPAQUE
OMNIPAQUE is a drug associated with $779,991 in payments to 8 healthcare providers, recorded across 32 transactions in the CMS Open Payments database. The primary manufacturer is GE HEALTHCARE.
Payment data is available from 2017 to 2023. In 2023, $198,551 was paid across 12 transactions to 0 doctors.
The most common payment nature for OMNIPAQUE is "Unspecified" ($767,576, 98.4% of total).
OMNIPAQUE is associated with 5 research studies, including "A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF URATE EVALUATING INOSINE TREATMENT TO SLOW CLINICAL DECLINE IN EARLY PARKINSONS DISEASE" ($384,600).